Skip to content

US · LFMD · MEDICAL - PHARMACEUTICALS

LifeMD, Inc. (LFMD) intrinsic value and stock valuation

$1.45as of 2026-11-21 · Mkt cap 172.17M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

LifeMD, Inc. DCF and intrinsic value

InvestorsCraft values LFMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LFMD’s statements →

LifeMD, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals New York City, NY 10001 lifemd.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$194.1M+39.1% 5y CAGRd
20112025
Net income
-$-7.11M
20112025
Free cash flow
-$-1.24M
20112025
Total equity
$23.2M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$194.1M$212.5M$152.6M$119M$92.9M
Operating income-$-7.67M-$-16.14M-$-14.49M-$-43.45M-$-54.3M
Net income-$-7.11M-$-18.88M-$-20.6M-$-45.54M-$-60.9M
EPSd-$-157.54K-$-458.25K-$-607.49K-$-1.47M-$-2.25M
Operating cash flow$8.28M$17.5M$8.82M-$-22.94M-$-33.09M
Capital expenditure-$-9.52M-$-11.54M-$-8.73M-$-12.89M-$-3.4M
Free cash flow-$-1.24M$5.98M$90K-$-35.83M-$-36.49M
Total assets$70.4M$72.5M$58.5M$25.7M$49.9M
Total debt$6.32M$25.1M$18.9M$4.13M$1.85M
Net debt-$-30.46M-$-9.9M-$-14.21M$170K-$-39.48M
Total equity$23.2M-$-4.05M$5.57M-$-7.31M$25.8M
Cash and short-term investments$36.8M$35M$33.2M$3.96M$41.3M
Income statement
20252024202320222021
Revenue$194.1M$212.5M$152.6M$119M$92.9M
Cost of revenue$39.3M$24.1M$18.9M$18.7M$18M
Gross profit$154.8M$188.4M$133.7M$100.4M$74.9M
Research and development expenses$7.35M$9.51M$6.06M$2.97M$950K
Selling, general and administrative expenses$144M$175.7M$128.2M$125.3M$122.1M
Other expenses$11.1M$19.3M$13.9M$15.5M$6.16M
Operating expenses$162.4M$204.5M$148.1M$143.8M$129.2M
Cost and expenses$201.7M$228.6M$167M$162.5M$147.2M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$1.36M$2.18M$2.6M$1.28M$3.02M
Depreciation and amortization$7.31M$9.49M$6.6M$1.09M$360K
Ebitda-$-1.52M-$-6.65M-$-8.21M-$-38.6M-$-57.94M
Operating income-$-7.67M-$-16.14M-$-14.49M-$-43.45M-$-54.3M
Total other income/expenses, net-$-2.52M-$-2.18M-$-2.92M-$-1.21M-$-7.02M
Income before tax-$-10.19M-$-18.33M-$-17.41M-$-44.66M-$-61.32M
Income tax expense$50K$400K$430K$360K$10K
Net income-$-7.11M-$-18.88M-$-20.6M-$-45.54M-$-60.9M
Weighted average shares outstanding$45.1M$41.2M$33.9M$31M$27M
Weighted average diluted shares outstanding$45.1M$41.2M$33.9M$31M$27M
Balance sheet
20252024202320222021
Cash and short-term investments$36.8M$35M$33.2M$3.96M$41.3M
Net receivables$9.31M$8.22M$5.28M$2.83M$980K
Inventory$2.77M$2.8M$2.76M$3.7M$1.62M
Total current assets$51.8M$48.7M$42.6M$11.3M$44.9M
Property, plant and equipment, net$5.27M$7.88M$1.07M$1.68M$1.99M
Goodwill and intangible assets$260K$15.9M$14.8M$12.7M$3.02M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$18.6M$23.7M$15.9M$14.4M$5M
Total assets$70.4M$72.5M$58.5M$25.7M$49.9M
Accounts payable$14.2M$16M$11.1M$10.1M$9.06M
Short-term debt$640K$8.95M$930K$3.55M$670K
Deferred revenue$10.8M$14.5M$8.83M$5.55M$1.5M
Total current liabilities$41.6M$60.3M$34.8M$31.4M$22.8M
Long-term debt$5.68M$16.2M$18M$570K$1.18M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.68M$16.3M$18.1M$1.6M$1.28M
Capital lease obligations$6.32M$6.77M$680K$1.33M$1.79M
Total liabilities$47.3M$76.5M$52.9M$33M$24.1M
Common stock$470K$420K$380K$320K$310K
Retained earnings-$-228.6M-$-236.25M-$-214.27M-$-190.56M-$-141.92M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$23.2M-$-4.05M$5.57M-$-7.31M$25.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$6.32M$25.1M$18.9M$4.13M$1.85M
Net debt-$-30.46M-$-9.9M-$-14.21M$170K-$-39.48M
Cash flow statement
20252024202320222021
Net income$15.6M-$-18.73M-$-20.6M-$-45.02M-$-61.32M
Depreciation and amortization$330K$9.49M$6.6M$3.77M$870K
Stock-based compensation$10.5M$12.2M$12.5M$13.7M$12.1M
Change in working capital-$-7.85M$12.7M$4.91M-$-1.55M$9.13M
Accounts receivable$1.15M-$-2.94M-$-2.44M-$-2.19M$20K
Inventory$300K$680K$760K-$-2.18M-$-410K
Accounts payable$3.24M$4.92M$980K$1.25M-$-890K
Net cash provided by operating activities$8.28M$17.5M$8.82M-$-22.94M-$-33.09M
Investments in property, plant and equipment-$-1.87M-$-1.49M-$-200K-$-370K-$-250K
Acquisitions, net$0.00$0.00$0.00-$-1.01M$0.00
Net cash used for investing activities$6.91M-$-11.54M-$-8.73M-$-13.91M-$-3.4M
Common stock issued$9.19M$0.00$16.2M$0.00$14M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-3.11M-$-3.11M-$-3.11M-$-3.11M-$-870K
Net cash used for financing activities-$-13.41M-$-4.12M$29.1M-$-530K$68.6M
Net change in cash$1.78M$1.86M$29.2M-$-37.37M$32.2M
Cash at end of period$36.8M$35M$33.2M$3.96M$41.3M
Operating cash flow$8.28M$17.5M$8.82M-$-22.94M-$-33.09M
Capital expenditure-$-9.52M-$-11.54M-$-8.73M-$-12.89M-$-3.4M
Free cash flow-$-1.24M$5.98M$90K-$-35.83M-$-36.49M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About LifeMD, Inc.

        LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical device, and custom-compounded topical treatments for both male and female hair loss. RexMD serves as a men's telehealth brand, providing virtual medical treatment from licensed providers for a wide array of male-specific health needs. LifeMD Primary Care offers a personalized, subscription-based virtual primary care solution, addressing routine, urgent, and chronic health management requirements. This mobile-centric platform integrates remote consultations, medication management, diagnostic services, and imaging referrals. Cleared is a telehealth service dedicated to offering personalized therapies for allergic, asthmatic, and immunological conditions. Nava MD stands as a skincare and tele-dermatology brand catering specifically to women, facilitating virtual access to dermatologists and other specialists for medical treatment. Additionally, the company provides PDFSimpli, a cloud-based software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents online. LifeMD distributes its offerings directly to individuals, via its own e-commerce channels, and through collaborations with external partners. Originally established in 1994 as Conversion Labs, Inc., the company rebranded to LifeMD, Inc. in February 2021 and is headquartered in New York City.

        CEO
        Justin Schreiber
        Employees
        389
        Beta
        1.99

        Explore

        Frequently asked questions

        What is the intrinsic value of LifeMD, Inc. (LFMD)?

        InvestorsCraft does not currently publish an intrinsic value for LFMD. How the IC value is calculated.

        Is LFMD undervalued?

        InvestorsCraft does not publish an undervaluation signal for LFMD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.